Podocyte Gene Therapy Seems Promising for IgAN in Preclinical Research
Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.
Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH
Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
Abdellatif discussed the high prevalence of gout in patients with chronic kidney disease and the importance of screening and early treatment.
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.
Felzartamab Slows IgAN Decline in New Phase 2 Data
Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.
Low-Dose CAR-T Shows Efficacy in Pediatric Systemic Lupus Erythematosus
Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.
Kidney Compass: FLOW Insights from Kidney Week 2024, with Katherine Tuttle, MD
Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.
Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout
Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.
Carla Nester, MD: 12-Month Data Informs Potential of Iptacopan in C3 Glomerulopathy
Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.
12-Month APPEAR-C3G Data Highlight Potential of Iptacopan in C3 Glomerulopathy
The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.
Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
Kidney Compass: Atacicept for IgAN with Jonathan Barratt, MD, PhD, at Kidney Week 2024
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy
New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
Richard Pratley, MD: FLOW Mortality Data and Allocation Strategies for Semaglutide
Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities
Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.
Carla Nester, MD: Pegcetacoplan in C3 Glomerulopathy and Primary IC-MPGN
Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN .
VALIANT: Pegcetacoplan Offers Benefit for UPCR, eGFR, C3 Staining in C3G, IC-MPGN
VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.
KAT-AKI: Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients
Yale's KAT-AKI trial found personalized EHR alerts for AKI management improved clinician actions but didn't reduce progression, dialysis, or mortality rates in patients.
Ladan Zand, MD: Obinutuzumab a Promising Option for Refractory, Primary FSGS
Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.
Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.
Finerenone Use Reduces UACR, New-Onset Macroalbuminuria in Heart Failure Patients
New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.
DUPLEX: Sparsentan Could Offer Greater Benefit in Genetic FSGS
A posthoc analysis of the DUPLEX trial suggests patients with genetic FSGS may experience a more pronounced and sustained antiproteinuric response with sparsentan.
Obinutuzumab Reduced Proteinuria, Improved eGFR in FSGS
Overall, 8 of 20 patients had complete or partial remission of their FSGS.
Recurrent UTIs Could Damage Kidneys, Even Without Apparent Scarring
RIVUR analysis suggests recurrent UTIs in children with VUR may lower eGFR, even without kidney scarring, especially in those with multiple febrile infections.
Sibeprenlimab Meaningfully Reduces uPCR in Adults With IgA Nephropathy
The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.
